Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natco Claims Sole Exclusivity For Ibrutinib Tablets

Claims US 180-Day Exclusivity On Four Strengths Of Imbruvica Rival

Executive Summary

Natco says it will be entitled to 180-day exclusivity for four strengths of ibrutinib tablets in the US after receiving tentative FDA approval.

You may also be interested in...



Alvogen And Natco Facing Decade Wait On Ibrutinib After US Appeal Fails

The US Court of Appeals rejected all arguments brought by Alvogen and Natco in their appeal against an unfavorable lower court Imbruvica (ibrutinib) ruling, leaving the ANDA sponsors facing a significant wait to potential approval and launch.

Natco Gets US Front-End Through Dash Acquisition

India’s Natco Pharma has struck an $18m deal to acquire New Jersey-based Dash Pharmaceuticals in a bid to acquire a “direct front-end marketing footprint” in the US.

Alvogen Imbruvica Ruling Set To Push AbbVie’s Monopoly To 2032

Alvotech and Natco have failed to persuade a US court that certain of AbbVie’s IP shielding its Imbruvica blockbuster is invalid. In response, the originator said that it did not anticipate generic competition to its branded oral therapy for treating forms of cancer until March 2032, assuming pediatric exclusivity is granted.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel